ConductScience.org, home

Paper3940216

CB 1954 revisited. I. Disposition kinetics and metabolism.

Workman P and 2 others. Cancer Chemother Pharmacol, 1986. Cited by 31 papers, by iCite.

Cite this record

ConductScience Library. CB 1954 revisited. I. Disposition kinetics and metabolism. Papers, record 3940216. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3940216

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CB 1954 revisited. I. Disposition kinetics and metabolism.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1986
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
31
iCite
Relative citation ratio, by iCite
1.32
iCite
Revised in PubMed
2019-08-29
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Workman PP
2White RAR A
3Talbot KK

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AziridinesMajor topic
AzirinesMajor topic
Allopurinol
Animals
Biotransformation
Brain
Dogs
Drug Interactions
Kinetics
Male
Metabolic Clearance Rate
Mice
Mice, Inbred Strains
Neoplasms, Experimental
Phenobarbital

Source PubMed

Download CSV of topics

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17273265Structure-pharmacokinetic relationships for misonidazole analogues in mice.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7273265PubMed
21170190Medicinal nitro-compounds. Part II. Search for ortho-interactions in tumour-inhibitory 2,4-dinitrophenylaziridines.J Chem Soc Perkin 11975https://conductscience.org/library/papers/1170190PubMed
35404002A spectrophotometric method for the estimation of the carcinostatic agent, 5-aziridino-2,4-dinitrobenzamide (CB 1954), in biological fluids.Biochem Pharmacol1969https://conductscience.org/library/papers/5404002PubMed
47313077Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide).Radiat Res1981https://conductscience.org/library/papers/7313077PubMed
5985569The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).Biochem Pharmacol1976https://conductscience.org/library/papers/985569PubMed
6528273The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin.Int J Radiat Oncol Biol Phys1979https://conductscience.org/library/papers/528273PubMed
77002161Selective inhibition of ribonucleotide reductase by the monofunctional alkylating agent 5(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).Biochem Pharmacol1980https://conductscience.org/library/papers/7002161PubMed
86547051Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.Br J Cancer1984https://conductscience.org/library/papers/6547051PubMed
96932916The response of a human tumour xenograft to chemotherapy: intrinsic variation between tumours and its significance in planning experiments.Br J Cancer Suppl1980https://conductscience.org/library/papers/6932916PubMed
105156332Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships. II.Chem Biol Interact1971https://conductscience.org/library/papers/5156332PubMed
1143079902,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.Biochem Pharmacol1969https://conductscience.org/library/papers/4307990PubMed
125407053Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships.Chem Biol Interact1969https://conductscience.org/library/papers/5407053PubMed
137370166Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.Br J Cancer1980https://conductscience.org/library/papers/7370166PubMed
146466543Preclinical pharmacokinetics of benznidazole.Br J Cancer1984https://conductscience.org/library/papers/6466543PubMed
154855748Studies on the mechanism of action of 5-aziridinyl-2, 4-dinitrobenzamide in tumor cells.Cancer Res1974https://conductscience.org/library/papers/4855748PubMed
163940225CB 1954 revisited. II. Toxicity and antitumour activity.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3940225PubMed
17940937Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers.Radiat Res1976https://conductscience.org/library/papers/940937PubMed
187460192Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/7460192PubMed
19659541Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography.J Chromatogr1978https://conductscience.org/library/papers/659541PubMed
2036083Metabolic activation of nitrofurantoin--possible implications for carcinogenesis.Biochem Pharmacol1979https://conductscience.org/library/papers/36083PubMed

See all 28 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.

PMIDTitleJournalYearIn PapersSource
19924084Bystander or no bystander for gene directed enzyme prodrug therapy.Molecules2009https://conductscience.org/library/papers/19924084PubMed
17768344Crystallization and preliminary X-ray characterization of the Bacillus amyloliquefaciens YwrO enzyme.Acta Crystallogr Sect F Struct Biol Cryst Commun2007https://conductscience.org/library/papers/17768344PubMed
12888809Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.Br J Cancer2003https://conductscience.org/library/papers/12888809PubMed
8375021The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).Cancer Metastasis Rev1993https://conductscience.org/library/papers/8375021PubMed
3940225CB 1954 revisited. II. Toxicity and antitumour activity.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3940225PubMed
3168141Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3168141PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3940216

GET https://conductscience.org/api/papers/v1/3940216/references?page=2